RxDoctor Payments Data

Alison Rickerson, PA

Physician Assistant · Houston, TXNPI 1093405219

Payments from drug & device makers

$1,988in general payments, 2019–2025

Across 79 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$836
  • Pfizer$381
  • Teva Pharmaceuticals USA, Inc.$183
  • Lundbeck LLC$167
  • Axsome Therapeutics, Inc.$155
  • Impel Pharmaceuticals LLC$72
  • plus $194 from 5 others

What the payments were for

  • Food & beverage$1,988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie35$836
Pfizer15$381
Teva Pharmaceuticals USA, Inc.8$183
Lundbeck LLC8$167
Axsome Therapeutics, Inc.2$155
Impel Pharmaceuticals LLC3$72
Johnson & Johnson2$54
Merz Pharmaceuticals, LLC1$45
Lilly USA, LLC2$42
Tonix Medicines, Inc.2$30
Supernus Pharmaceuticals, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,988 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$118,129
Medicare patients
73
Services billed
16,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe58$58,552
QuliptaAtogepant38$56,710
Emgality PenGalcanezumab-Gnlm57$49,257
Ajovy SyringeFremanezumab-Vfrm12$19,518
Emgality SyringeGalcanezumab-Gnlm15$17,674
Sumatriptan Succinate126$12,724
LyricaPregabalin12$9,365
Zolmitriptan15$4,559
Naratriptan Hcl94$2,434
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine82$1,578
Eletriptan HbrEletriptan Hydrobromide19$1,271
RizatriptanRizatriptan Benzoate47$1,025
Duloxetine Hcl34$967
Gabapentin56$789
Tizanidine Hcl64$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$836$56,71038 claims
PfizerLyrica$381$9,36512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →